What is the recommended heparin dosing regimen for acute portal vein thrombosis in an adult?

Portal Vein Thrombosis: Heparin Dosing in Adults

Recommended Anticoagulation Approach

For acute portal vein thrombosis in cirrhotic adults, use therapeutic-dose low-molecular-weight heparin (LMWH) rather than unfractionated heparin, with enoxaparin 1 mg/kg subcutaneously twice daily or 1.5 mg/kg once daily as the preferred regimen. 1, 2

While unfractionated heparin (UFH) is FDA-approved for venous thromboembolism and can be used for portal vein thrombosis, current guidelines and evidence favor LMWH or direct oral anticoagulants for this indication. 1, 2

If Unfractionated Heparin Must Be Used

When UFH is selected (e.g., severe renal impairment with creatinine clearance <30 mL/min, need for rapid reversibility, or institutional preference), use the standard weight-based VTE dosing regimen: 3, 4

• Initial bolus: 80 units/kg IV
• Continuous infusion: 18 units/kg/hour
• Target aPTT: 1.5–2.5 times control (corresponding to anti-Factor Xa level 0.3–0.7 IU/mL) 3, 5, 6

Monitoring Protocol for UFH

• Check first aPTT 4–6 hours after starting infusion 5, 6, 4
• After any dose adjustment, recheck aPTT in 6–10 hours 5, 6
• Once therapeutic, monitor aPTT daily 5, 6
• Monitor platelet count every 2–3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia 3

Preferred LMWH Regimens for Portal Vein Thrombosis

The evidence strongly supports LMWH over UFH for portal vein thrombosis in cirrhosis. 1, 2 Specific dosing options include:

• Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily 3
• Dalteparin: 200 units/kg subcutaneously once daily for 1 month, then 150 units/kg once daily 7, 8, 9

Evidence Supporting LMWH Over UFH

A 2023 study demonstrated that weight-based LMWH dosing (same as VTE regimens) achieved better recanalization rates than fixed dosing in cirrhotic patients with portal vein thrombosis, with no increase in bleeding complications. 9 The 2025 AGA guidelines explicitly recommend LMWH as a reasonable first-line option alongside vitamin K antagonists and DOACs. 1

Clinical Decision Algorithm

Step 1: Assess Severity and Timing

• Recent thrombosis (<6 months) with >50% occlusion or main portal vein involvement: Anticoagulation strongly recommended 1
• Chronic thrombosis (>6 months) with complete occlusion and cavernous transformation: Anticoagulation not advised 1
• Intestinal ischemia present: Urgent anticoagulation required regardless of other factors 1

Step 2: Select Anticoagulant Based on Liver Function

• Child-Pugh A or B cirrhosis: LMWH, DOACs, or vitamin K antagonists are all reasonable; DOACs offer convenience without INR monitoring 1, 2
• Child-Pugh C cirrhosis: LMWH alone preferred (or as bridge to warfarin if baseline INR is normal) 2
• Severe renal impairment (CrCl <30 mL/min): Avoid LMWH; use UFH with aPTT monitoring 3

Step 3: Address Thrombocytopenia

• Platelet count >50 × 10⁹/L: Full-dose anticoagulation 2
• Platelet count <50 × 10⁹/L: Individualize based on thrombus extent, progression risk, and bleeding risk; do not automatically withhold anticoagulation 2

Critical Pitfalls to Avoid

Delayed initiation of anticoagulation significantly reduces recanalization rates. 1 Do not delay treatment for endoscopic variceal screening—screen concurrently or after starting anticoagulation. 1

Fixed-dose heparin protocols are inferior to weight-based dosing for achieving therapeutic anticoagulation rapidly, increasing early recurrent thrombosis risk. 3, 6, 9

Premature discontinuation of heparin before adequate oral anticoagulation (INR ≥2.0 for two consecutive days when bridging to warfarin) increases recurrent thromboembolism risk. 5, 6, 4

Failure to monitor for heparin-induced thrombocytopenia in patients receiving UFH can lead to catastrophic arterial and venous thrombosis; platelet monitoring is mandatory. 3

Duration and Monitoring

• Obtain cross-sectional imaging every 3 months to assess treatment response 1
• Continue anticoagulation until clot resolution in non-transplant candidates, or indefinitely until transplantation in transplant candidates 1
• If clot regresses, continue anticoagulation; if no response after 6 months, reassess risk-benefit 1